59 related articles for article (PubMed ID: 18058075)
1. Novel postremission strategies in adults with acute myeloid leukemia.
Lancet JE; Karp JE
Curr Opin Hematol; 2009 Mar; 16(2):105-11. PubMed ID: 19468272
[TBL] [Abstract][Full Text] [Related]
2. Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe.
Berdel WE
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267614
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia: focus on novel therapeutic strategies.
Lin TL; Levy MY
Clin Med Insights Oncol; 2012; 6():205-17. PubMed ID: 22654526
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia stem cells: seek and destroy.
Roboz GJ; Guzman M
Expert Rev Hematol; 2009 Dec; 2(6):663-72. PubMed ID: 21082958
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of malignant systemic diseases: hemoblastoses and malignant lymphomas].
Schmidt CG
Arzneimittelforschung; 1987 Feb; 37(2A):279-87. PubMed ID: 3551972
[TBL] [Abstract][Full Text] [Related]
6. Maintenance for acute myeloid leukemia revisited.
Büchner T; Krug U; Berdel WE; Heinecke A; Sauerland MC; Wörmann B; Hiddemann W
Curr Treat Options Oncol; 2007 Aug; 8(4):296-304. PubMed ID: 18058075
[TBL] [Abstract][Full Text] [Related]
7. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
8. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
9. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig WD; Fischer J; Aul HC; Vaupel HA; Kuse R; Zeile G
J Clin Oncol; 1985 Dec; 3(12):1583-9. PubMed ID: 3906048
[TBL] [Abstract][Full Text] [Related]
10. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Büchner T; Schlenk RF; Schaich M; Döhner K; Krahl R; Krauter J; Heil G; Krug U; Sauerland MC; Heinecke A; Späth D; Kramer M; Scholl S; Berdel WE; Hiddemann W; Hoelzer D; Hehlmann R; Hasford J; Hoffmann VS; Döhner H; Ehninger G; Ganser A; Niederwieser DW; Pfirrmann M
J Clin Oncol; 2012 Oct; 30(29):3604-10. PubMed ID: 22965967
[TBL] [Abstract][Full Text] [Related]
11. Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine.
Visani G; Olivieri A; Malagola M; Brunori M; Piccaluga PP; Capelli D; Pomponio G; Martinelli G; Isidori A; Sparaventi G; Leoni P
Leuk Lymphoma; 2006 Jun; 47(6):1091-102. PubMed ID: 16840201
[TBL] [Abstract][Full Text] [Related]
12. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Cornelissen JJ; van Putten WL; Verdonck LF; Theobald M; Jacky E; Daenen SM; van Marwijk Kooy M; Wijermans P; Schouten H; Huijgens PC; van der Lelie H; Fey M; Ferrant A; Maertens J; Gratwohl A; Lowenberg B
Blood; 2007 May; 109(9):3658-66. PubMed ID: 17213292
[TBL] [Abstract][Full Text] [Related]
13. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Büchner T; Berdel WE; Schoch C; Haferlach T; Serve HL; Kienast J; Schnittger S; Kern W; Tchinda J; Reichle A; Lengfelder E; Staib P; Ludwig WD; Aul C; Eimermacher H; Balleisen L; Sauerland MC; Heinecke A; Wörmann B; Hiddemann W
J Clin Oncol; 2006 Jun; 24(16):2480-9. PubMed ID: 16735702
[TBL] [Abstract][Full Text] [Related]
14. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
